Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 93.63M P/E - EPS this Y 27.90% Ern Qtrly Grth -
Income -30.7M Forward P/E -1.70 EPS next Y -87.10% 50D Avg Chg -10.00%
Sales 56.54M PEG -0.04 EPS past 5Y - 200D Avg Chg -4.00%
Dividend N/A Price/Book 3.49 EPS next 5Y 61.20% 52W High Chg -50.00%
Recommedations 1.60 Quick Ratio 1.45 Shares Outstanding 90.62M 52W Low Chg 126.00%
Insider Own 7.53% ROA -30.38% Shares Float 76.81M Beta 1.01
Inst Own 30.63% ROE -358.92% Shares Shorted/Prior 195.38K/221.36K Price 1.04
Gross Margin -30.22% Profit Margin -54.29% Avg. Volume 876,140 Target Price 5.60
Oper. Margin -67.27% Earnings Date Apr 18 Volume 710,387 Change 0.00%
About Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cidara Therapeutics, Inc. News
04/05/24 Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
03/06/24 Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024
02/15/24 Steven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio
02/12/24 Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
01/29/24 Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
12/26/23 Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
12/22/23 Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
12/07/23 Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
12/06/23 Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
11/30/23 Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
11/20/23 Cidara Therapeutics Named as a San Diego Metro Area Top Workplace
11/03/23 Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting
11/02/23 Cidara Therapeutics Inc (CDTX) Reports Q3 2023 Financial Results
11/02/23 Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
10/21/23 Cidara Therapeutics (NASDAQ:CDTX) Is In A Strong Position To Grow Its Business
10/13/23 Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)
10/11/23 Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023
09/29/23 Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/27/23 Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
09/14/23 Insider Sell: Chief Scientific Officer Leslie Tari Sells 18,469 Shares of Cidara Therapeutics Inc
CDTX Chatroom

User Image supernoob Posted - 13 seconds ago

$CDTX no news is good news ?

User Image HypnoTrader Posted - 2 hours ago

$CDTX companies tend to go down prior to anticipated R/S events, even though the value of the company remains the same....

User Image SDCidara Posted - 2 hours ago

$CDTX I get everyone is nervous but I've been invested in Cidara for 8 years. The company doesn't put out press releases unless material news. The company is actually in better position today than it has ever been with Rezzayo approved (Japan rights still owned by Cidara), CD388 (influenza drug) still in play and promising cancer drugs.

User Image Ulanbek Posted - 3 hours ago

$CDTX the same price every trade day. Nothing changes

User Image SpyWolf Posted - 4 hours ago

$CDTX We Know all of you are paid bashers! You have no power here! I'm buying even more!

User Image RealAvidTrader Posted - 4 hours ago

$CDTX Lets see whether I am smart or a dummy for loading at these levels. Everything on the surface is negative sentiment wise. Possible dilution, but I like the stock… How much more downside could there be??? Time will tell 🫡

User Image twitofstock Posted - 4 hours ago

$CDTX why don't they anounce the r/s, why wait till the last moment, i don't see the logic.

User Image supernoob Posted - 6 hours ago

$CDTX

User Image Enodloca Posted - 6 hours ago

$CDTX 156,684 shares traded so far. People on the sidelines just waiting.

User Image _nic Posted - 6 hours ago

$CDTX halted? 🤡

User Image MAGAKing24 Posted - 8 hours ago

$CDTX added a cool 900 shares.

User Image Shawhwk Posted - 9 hours ago

$CDTX

User Image CaliEmpress Posted - 10 hours ago

$CDTX Oh goodness stop with the drama and conspiracy theories already. Buy and hold then add some more and be still shhhhhhh

User Image SpyWolf Posted - 10 hours ago

$CDTX Hold your shares no matter what these creeps put out on this chat! They are lying through their teeth like a big fat rug! Hold your cards close to your chest! Iam reporting false information to the SEC because I'm the only real man on here!

User Image DogePeoplesCoin Posted - 11 hours ago

$CDTX Extension of 180 days is the most likelihood here. I don’t see any reason why they won’t request and get granted as they are well qualified for the second 6 months compliance period!

User Image NaifNasserA Posted - 12 hours ago

$CDTX this week please

User Image NaifNasserA Posted - 17 hours ago

$CDTX Jeppson Wealth Management, Llc reports 4.35% increase in ownership of CDTX / Cidara Therapeutics, Inc.

User Image xxtpat Posted - 21 hours ago

$CDTX I have mentally finished with the RS. This does not change my percentage share in Codara. I think a market capitalisation of around $60m is too cheap considering Rezafungin and the rest of the pipeline. We'll know more in a few months.

User Image investor666 Posted - 1 day ago

$CDTX This looks more and more like truly mismanaged biotech . I wanted to add at 70 cents but I think I will wait to see if there is an R/S and wait. I guess this is all that any of us can do right now. This company embodies the problem with Bio. To the moon or to the gutter. We are closer to the gutter than the moon at this stage, that is for sure. It seems as if management has given up.

User Image Naseebwala Posted - 1 day ago

$CDTX @CaliEmpress what’s your read of tea leaves?

User Image TangoToEvora Posted - 1 day ago

$CDTX Now I look like a dumb for adding more yesterday during PM at 0.80$..LOL... IT seems like NASDAQ was already notified yesterday and the PR for RS will come out at the latest on Friday. RS on Tuesday next. Great science, horrible management! Fire the CFO, Jeff!

User Image ruffikat Posted - 1 day ago

$CDTX 😸

User Image SpyWolf Posted - 1 day ago

$CDTX Now we know for sure Jeff Stein is going to pull this off with a hug win, because all the basher shorts are going to come out of the woodwork like roaches!

User Image NaifNasserA Posted - 1 day ago

$CDTX Now we got 2 reasons why Cidara is not compliant

User Image sng383838 Posted - 1 day ago

$CDTX Wow...That's way way oversold !!!!!!!

User Image Andrew6666 Posted - 1 day ago

$CDTX Whether R/S or not I Hope Something comes out. We are in a "Fear limbo" now. What a pity 🥱

User Image cb1961 Posted - 1 day ago

$CDTX so it looks like on April 4, 2024 the board approved a reverse split 30 to 1.

User Image supernoob Posted - 1 day ago

$CDTX maybe we get lucky and get news Friday lol I know I’m dreaming

User Image _nic Posted - 1 day ago

$CDTX shenanigans

User Image kampochea Posted - 1 day ago

$CDTX ..like someone already mentioned...IF a buyout should be at the order...it's logic that those who are interested want to have the "books" (Cidara) OK. Ernst and Young are sure able to modify / rectify what have to be done.

Analyst Ratings
HC Wainwright & Co. Buy Apr 8, 24
HC Wainwright & Co. Buy Dec 7, 23
HC Wainwright & Co. Buy Nov 6, 23
Needham Buy Sep 22, 23
HC Wainwright & Co. Buy Sep 22, 23
Needham Buy Sep 8, 23
HC Wainwright & Co. Buy Sep 7, 23
HC Wainwright & Co. Buy Aug 7, 23
Needham Buy Aug 4, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Tari Leslie CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Aug 14 Buy 0.97 10,000 9,700 294,179 08/14/23
Stein Jeffrey President & CEO President & CEO Aug 08 Buy 0.9577 50,000 47,885 331,602 08/08/23
Stein Jeffrey President & CEO President & CEO Mar 27 Buy 1.0371 50,000 51,855 281,602 03/27/23
Ward Shane COO & CLO COO & CLO Mar 13 Sell 1.53 4,329 6,623 84,576 03/13/23
Tari Leslie CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Mar 13 Sell 1.53 7,562 11,570 190,179 03/13/23
Shah Preetam CFO & CBO CFO & CBO Mar 13 Sell 1.53 6,648 10,171 148,141 03/13/23
Sandison Taylor Chief Medical Office.. Chief Medical Officer Mar 13 Sell 1.53 7,203 11,021 288,550 03/13/23
Sandison Taylor Chief Medical Office.. Chief Medical Officer Sep 12 Sell 0.6849 18,478 12,656 291,753 09/13/22
Tari Leslie CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Sep 12 Sell 0.6849 18,159 12,437 193,741 09/13/22
Daruwala Paul Chief Operating Offi.. Chief Operating Officer Sep 12 Sell 0.6849 16,199 11,095 221,099 09/13/22
Johnson Brady Vice President, Fina.. Vice President, Finance Mar 21 Sell 0.81 654 530 49,366 03/23/22
Johnson Brady Vice President, Fina.. Vice President, Finance Mar 11 Sell 0.71 945 671 50,020 03/11/22
Daruwala Paul Chief Operating Offi.. Chief Operating Officer Dec 29 Option 0 9,900 192,431 01/07/22
Daruwala Paul Chief Operating Offi.. Chief Operating Officer Dec 29 Sell 1.25 5,133 6,416 187,298 01/07/22
Stein Jeffrey President & CEO President & CEO Dec 29 Option 0.00 20,000 489,878 01/07/22
Johnson Brady Vice President, Fina.. Vice President, Finance Dec 29 Option 0 262 51,381 01/07/22
Johnson Brady Vice President, Fina.. Vice President, Finance Dec 29 Sell 1.25 416 520 50,965 01/07/22
Sandison Taylor Chief Medical Office.. Chief Medical Officer Dec 29 Option 0.00 15,600 256,231 01/07/22
Tari Leslie Chief Scientific Off.. Chief Scientific Officer Dec 29 Option 0 2,101 156,652 01/07/22
Tari Leslie Chief Scientific Off.. Chief Scientific Officer Dec 29 Sell 1.25 1,252 1,565 155,400 01/07/22
Daruwala Paul Chief Operating Offi.. Chief Operating Officer Apr 05 Sell 2.36 3,461 8,168 50,531 04/05/21